BioScrip Newswire

BioScrip Newswire

Comprehensive Real-Time News Feed for BioScrip.

Results 1 - 20 of 167 in BioScrip

  1. Gamco Investors Inc. Et Al Sells 97,650 Shares of BioScrip IncRead the original story w/Photo

    8 hrs ago | AmericanBankingNews.com

    Gamco Investors INC. ET AL reduced its holdings in shares of BioScrip Inc by 12.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission .

    Comment?

  2. Jefferies Financial Group Brokers Raise Earnings Estimates for BioScrip IncRead the original story w/Photo

    Monday Nov 12 | AmericanBankingNews.com

    Equities research analysts at Jefferies Financial Group boosted their FY2018 earnings per share estimates for shares of BioScrip in a research note issued on Wednesday, November 7th. Jefferies Financial Group analyst B. Tanquilut now anticipates that the company will earn per share for the year, up from their previous forecast of .

    Comment?

  3. Barrington Research Research Analysts Lower Earnings Estimates for BioScrip IncRead the original story w/Photo

    Monday Nov 12 | AmericanBankingNews.com

    Analysts at Barrington Research dropped their FY2018 earnings per share estimates for shares of BioScrip in a research note issued to investors on Wednesday, November 7th. Barrington Research analyst M. Petusky now anticipates that the company will earn per share for the year, down from their prior estimate of .

    Comment?

  4. Contrasting BioScripRead the original story w/Photo

    Sunday Nov 11 | AmericanBankingNews.com

    BioScrip and New York Health Care are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings. 85.0% of BioScrip shares are owned by institutional investors.

    Comment?

  5. Comparing New York Health CareRead the original story w/Photo

    Sunday Nov 11 | AmericanBankingNews.com

    New York Health Care and BioScrip are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability. New York Health Care has a beta of -1.41, indicating that its share price is 241% less volatile than the S&P 500.

    Comment?

  6. BioScrip Inc (BIOS) to Post Q4 2019 Earnings of $0.01 Per Share, Barrington Research ForecastsRead the original story w/Photo

    Sunday Nov 11 | Daily Political

    Equities researchers at Barrington Research cut their Q4 2019 EPS estimates for BioScrip in a research report issued on Wednesday, November 7th. Barrington Research analyst M. Petusky now anticipates that the company will post earnings per share of $0.01 for the quarter, down from their previous forecast of $0.03.

    Comment?

  7. BioScrip (BIOS) Releases Earnings Results, Misses Estimates By $0.02 EPSRead the original story w/Photo

    Wednesday Nov 7 | IntersportsWire

    BioScrip announced its earnings results on Tuesday. The company reported earnings per share for the quarter, missing analysts' consensus estimates of by , Briefing.com reports.

    Comment?

  8. BioScrip, Inc. (BIOS) CEO Daniel Greenleaf on Q3 2018 Results - Earnings Call TranscriptRead the original story w/Photo

    Tuesday Nov 6 | Seeking Alpha

    Greetings, and welcome to BioScrip, Inc. Third Quarter Fiscal 2018 Financial Results Conference Call. [Operator Instructions].

    Comment?

  9. Teton Advisors Inc. Cuts Stake in BioScrip IncRead the original story w/Photo

    Tuesday Nov 6 | IntersportsWire

    Teton Advisors Inc. lowered its holdings in BioScrip Inc by 7.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission . The firm owned 500,000 shares of the company's stock after selling 40,000 shares during the quarter.

    Comment?

  10. BioScrip Inc (BIOS) Expected to Announce Quarterly Sales of $171.06 MillionRead the original story w/Photo

    Sunday Nov 4 | AmericanBankingNews.com

    Equities research analysts expect BioScrip Inc to post sales of $171.06 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for BioScrip's earnings, with the lowest sales estimate coming in at $169.70 million and the highest estimate coming in at $173.61 million.

    Comment?

  11. BioScrip Inc (BIOS) Holdings Reduced by Gilder Gagnon Howe & Co. LLCRead the original story w/Photo

    Wednesday Oct 31 | AmericanBankingNews.com

    Gilder Gagnon Howe & Co. LLC lowered its holdings in BioScrip Inc by 0.3% in the third quarter, according to the company in its most recent disclosure with the SEC.

    Comment?

  12. BioScrip (BIOS) Set to Announce Earnings on TuesdayRead the original story w/Photo

    Tuesday Oct 30 | AmericanBankingNews.com

    BioScrip will release its earnings data before the market opens on Tuesday, November 6th. Analysts expect BioScrip to post earnings of per share for the quarter.

    Comment?

  13. BioScrip Inc (BIOS) Receives $3.58 Average Price Target from AnalystsRead the original story w/Photo

    Sunday Oct 28 | Daily Political

    Shares of BioScrip Inc have been given an average recommendation of "Buy" by the six analysts that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company.

    Comment?

  14. BioScrip (BIOS) Upgraded by Zacks Investment Research to "Hold"Read the original story w/Photo

    Oct 13, 2018 | IntersportsWire

    According to Zacks, "BioScrip concluded the second quarter on a mixed note. Although revenues beat the consensus mark, the massive year-over-year decline was a dampener.

    Comment?

  15. BioScrip (BIOS) Stock Rating Lowered by BidaskClubRead the original story w/Photo

    Oct 13, 2018 | IntersportsWire

    BIOS has been the subject of several other reports. Zacks Investment Research lowered BioScrip from a "buy" rating to a "hold" rating in a research report on Monday, August 6th.

    Comment?

  16. BioScrip Inc (BIOS) Expected to Announce Quarterly Sales of $171.06 MillionRead the original story w/Photo

    Sep 24, 2018 | AmericanBankingNews.com

    Equities research analysts expect BioScrip Inc to report sales of $171.06 million for the current quarter, according to Zacks . Three analysts have issued estimates for BioScrip's earnings, with estimates ranging from $169.70 million to $173.61 million.

    Comment?

  17. BioScrip (BIOS) Upgraded to Strong-Buy at BidaskClubRead the original story w/Photo

    Sep 24, 2018 | Daily Political

    BIOS has been the topic of several other reports. Zacks Investment Research lowered shares of BioScrip from a buy rating to a hold rating in a research report on Monday, August 6th.

    Comment?

  18. Rhumbline Advisers Has $372,000 Holdings in BioScrip IncRead the original story w/Photo

    Sep 23, 2018 | Daily Political

    Rhumbline Advisers raised its position in shares of BioScrip Inc by 16.9% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 126,878 shares of the company's stock after buying an additional 18,372 shares during the period.

    Comment?

  19. Zacks: Analysts Anticipate BioScrip Inc (BIOS) to Post -$0.07 EPSRead the original story w/Photo

    Sep 22, 2018 | The Breeze

    Equities analysts predict that BioScrip Inc will announce earnings of per share for the current quarter, according to Zacks Investment Research . Three analysts have issued estimates for BioScrip's earnings, with the highest EPS estimate coming in at and the lowest estimate coming in at .

    Comment?

  20. BioScrip Inc (BIOS) Stake Lessened by Venor Capital Management LPRead the original story w/Photo

    Sep 13, 2018 | Daily Political

    Venor Capital Management LP reduced its holdings in shares of BioScrip Inc by 1.5% during the second quarter, HoldingsChannel reports. The firm owned 14,425,087 shares of the company's stock after selling 226,205 shares during the period.

    Comment?